Related Experiment Video

Updated: Jun 21, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

[Efficacy of immunosuppressive therapy in children with acquired aplastic anemia]

Shu-chun Wang1, Yao Zou, Xiao-juan Chen

  • 1Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin, China.

Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics
|July 4, 2009
PubMed

Insights

For children with severe aplastic anemia (SAA) lacking an HLA-matched sibling, rabbit anti-T-lymphocyte globulin (R-ATG) combined with cyclosporine A (CSA) significantly improves survival outcomes compared to other immunosuppressive therapy (IST) regimens.

Area of Science:

  • Pediatric Hematology
  • Immunosuppressive Therapy
  • Aplastic Anemia Research

Background:

  • Acquired severe aplastic anemia (SAA) in children without an HLA-matched sibling presents a significant therapeutic challenge.
  • Evaluating the efficacy of different immunosuppressive therapy (IST) regimens is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To compare the effectiveness of three distinct IST regimens in treating pediatric SAA patients lacking an HLA-matched sibling.
  • To identify the optimal IST regimen that offers the best survival advantage.

Main Methods:

  • Retrospective analysis of 112 pediatric SAA patients treated between 2000 and 2006.
  • Patients were randomized to receive IST regimen I (cyclosporine A alone), IST regimen II (cyclosporine A and intravenous immunoglobulin), or IST regimen III (rabbit anti-T-lymphocyte globulin and cyclosporine A).
  • All patients received supportive therapy with stanozolol or testosterone propionate.

Main Results:

  • IST regimen III demonstrated a significantly higher response rate (62.5%) compared to IST regimen I (26.92%) and IST regimen II (33.33%) (P = 0.001).
  • Five-year overall survival rates were 20.50% for regimen I, 39.77% for regimen II, and 66.27% for regimen III.
  • No significant difference in response was observed between IST regimens I and II.

Conclusions:

  • The combination of rabbit anti-T-lymphocyte globulin (R-ATG) and cyclosporine A (CSA) is the most effective IST regimen for children with SAA who do not have an HLA-matched sibling.
  • This R-ATG and CSA combination provides a substantial 5-year survival advantage for these patients.
Abstract

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...